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Abstract17
A series of polyvinylpyrrolidone (PVP) fibers loaded with paracetamol (PCM) and caffeine18
(CAF) was fabricated by electrospinning and explored as potential oral fast-dissolving films.19
The fibers take the form of uniform cylinders with smooth surfaces, and contain the drugs in20
the amorphous form. Drug-polymer intermolecular interactions were evidenced by infrared21
spectroscopy and molecular modelling. The properties of the fiber mats were found to be22
highly appropriate for the preparation of oral fast dissolving films: their thickness is around23
120 – 130 µm, and the pH after dissolution in deionized water lies in the range of 6.7 to 7.2.24
Except at the highest drug loading, the folding endurance of the fibers was found to be > 2025
times. A flavoring agent can easily be incorporated into the formulation.26
The fiber mats are all seen to disintegrate completely within 2 s when added to simulated27
saliva solution. They release their drug cargo within around 150 s in a dissolution test, and28
to undergo much more rapid dissolution than is seen for the pure drugs. The data reported29
herein clearly demonstrate that the electrospun PCM/CAF fibers comprise excellent30
candidates for oral fast-dissolving films, which could be particularly useful for children and31
patients with swallowing difficulties.32
33
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1. Introduction42
Fast-dissolving drug delivery systems (FD-DDSs) were first developed in the late 1970s and43
rapidly gained interest in the pharmaceutical industry (Chaudhary et al., 2013; Hoffmann et44
al., 2011). These delivery systems either dissolve or disintegrate in the mouth very rapidly,45
without requiring any water to aid in swallowing. By releasing their drug cargo directly in the46
mouth, they enhance bioavailability and deliver rapid onset of action (Seager, 1998). FD-47
DDSs are available in the form of tablets (Pathan et al., 2013), films (Yu et al., 2009), wafers48
(Boateng et al., 2010; El-Mahrouk et al., 2014) and buccal (Dinge and Nagarsenker, 2008) or49
sublingual patches (Vrbata et al., 2013). Examples currently in the market include Zuplenz®50
(an oral soluble film used for the prevention of chemotherapy-induced, radiotherapy-51
induced, and postoperative nausea and vomiting) and Suboxone® (a sublingual film for the52
treatment of opioid dependence). Various other oral dissolving film formulations are in the53
pipeline, for example to treat central nervous system conditions such as Parkinson’s disease,54
schizophrenia or Alzheimer’s disease (Hoffmann et al., 2011).55
Sublingual films in particular have many advantages compared to other dosage forms: these56
include rapid onset of action, avoidance of first past metabolism, and convenient and non-57
invasive administration (Dixit and Puthli, 2009; Hearnden et al., 2012). There are however58
also some limitations. The relatively small surface area in the sublingual mucosa means that59
it is possible for the drug to be washed away with saliva before it can permeate the mucosal60
membrane. In addition, the tendency for involuntary swallowing of liquids greater in volume61
than 200 µL can lead to the dissolved drug entering the gastro-intestinal tract rather than62
being absorbed in the mouth. Dislodging of the formulation due to tongue movements can63
also lead to ineffective drug delivery (Squier and Wertz, 1993; Vrbata et al., 2013).64
Sublingual dosage forms are nevertheless highly beneficial for paediatric and geriatric65
patients, and also for any other patients with swallowing or digestion problems (Lam et al.,66
2014).67
There are several classical methods used to formulate fast dissolving thin films: solvent68
casting, semi-solid casting, hot melt extrusion, solid dispersion extrusion and rolling have all69
been investigated (Hoffmann et al., 2011; Liang and Chen, 2001; Low et al., 2013; Nagy et70
al., 2012; Ramineni et al., 2013). In recent years, the electrospinning technique has begun to71
be explored as an alternative route to such systems (Illangakoon et al., 2014; Luo et al.,72
2012; Williams et al., 2012). Electrospinning is a simple, rapid, inexpensive and easily73
scalable technique (Persano et al., 2013). It uses an electric field to create a charged jet of74
polymer solution. As this jet travels in air, the solvent evaporates leaving behind a charged75
fiber that can be collected on a metal screen (Doshi and Reneker, 1995). Electrospun fibers76
show great promise for developing many types of novel drug delivery systems (DDS) owing77
to their high surface area, high porosity, and ability to encapsulate high drug loadings (Cui et78
al., 2010; Raghavan et al., 2012; Reneker and Chun, 1996). The electrospinning technique79
can also easily be used to encapsulate more than one active pharmaceutical ingredient (API)80
(Natu et al., 2010; Wang et al., 2010; Xu et al., 2009).81
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The combination of paracetamol (PCM) and caffeine (CAF) was first approved for medical82
use by the UK Medicines and Healthcare Regulatory Authority (MHRA) in 1991 (MHRA,83
1991). PCM is a centrally acting analgesic, which is used to relieve mild to moderate pain in84
the body; it also acts as an antipyretic to help reduce body temperature. CAF is a mild85
stimulant which is often used in combination with analgesics, augmenting their effect86
(Diamond et al., 2000; Migliardi et al., 1994). Renner et al. showed that in humans the87
analgesic effects of PCM or PCM/CAF together, but not CAF alone, caused a significant88
reduction of pain-related cortical potentials from 30 minutes after medication (Renner et89
al., 2007). The PCM/CAF combination demonstrated greater effects than PCM alone90
throughout the 3 hour observation period.91
Recently Li et al. have fabricated poly(vinyl alcohol) fibers loaded with CAF or riboflavin by92
electrospinning (Li et al., 2013). In a dissolution study both drugs were released from the93
fiber matrices in a burst manner, with 100 % of the embedded CAF and 40 % of the94
riboflavin released within 60 s. Yu et al. have electrospun PCM with poly(vinyl pyrrolidone)95
(PVP) and compared the dissolution rate of the drug between electrospun, freeze dried,96
vacuum dried and heat dried membranes (Yu et al., 2010b). In vitro dissolution tests showed97
that the electrospun fibers released 93.8% of PCM within 2 minutes, with the dissolution98
rates observed being as follows: electrospun membrane > vacuum-dried membrane ≈ 99
freeze-dried membrane > heat-dried membrane.100
Paediatric oral formulations can be scientifically challenging to develop, and the twin101
necessities of both preparing a measurable dosage form which can be administered based102
upon body weight, and also of taste-masking, are key challenges unique to such103
formulations (Strickley et al., 2008). PCM poisoning has also been increasingly recognised in104
children (Heubi et al., 1998). In this work therefore, we set out to prepare PCM-containing105
oral fast dissolving films which could be safely and effectively administered to children.106
PVP K90 was selected as a film forming agent because it is a non-ionic, biocompatible, and107
biodegradable polymer featured on the FDA “generally regarded as safe” list (Bühler, 2005).108
The application of such polymers in DDSs is attractive because they have relatively well109
defined molecular weights and physicochemical characteristics (Ignatious et al., 2010). PVP110
also has mucoadhesive properties (Abdel-Hamid et al., 2007; Salamat-Miller et al., 2005). It111
has been widely used to prepare solid dispersions to improve the dissolution rates of poorly112
water-soluble drugs (Yu et al., 2009; Yu et al., 2010a). A range of commercial products such113
as Panadol ActiFast soluble tablets, Beechams’ cold relief orange flavor effervescent tablets,114
Hedex Extra, and Panadol Extra Advance all contain PVP.115
In this paper, we report the fabrication of PCM and CAF loaded electrospun PVP fibers. The116
resultant materials underwent detailed physicochemical characterization, and their117
dissolution properties were explored. A flavoring agent was also incorporated to enhance118
palatability.119
120
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2. Materials and methods121
2.1 Materials122
Paracetamol (PCM; batch 096K0072), caffeine (CAF; lot 38H0147), and polyvinylpyrrolidone123
(MW 360 000; PVP K90) (see Fig. 1) were purchased from Sigma Aldrich (Gillingham, UK).124
Concentrated raspberry flavor was purchased from Cottes’ Cordial (Tullamarine, Australia).125
All other chemicals used were of analytical grade and used as provided.126
127
2.2 Preparation of the composite nanofibers128
Anhydrous ethanol was selected as a spinning solvent, because it rapidly evaporates during129
electrospinning and both PCM and CAF are freely soluble in it. Ethanol is also classified by130
the FDA as a “Class 3” solvent, recommended for the formulation of oral fast dissolving thin131
films.132
A 10 % (w/v) PVP K90 solution was prepared by dissolving the appropriate amount of133
polymer in ethanol under stirring overnight. The desired amounts of PCM and CAF were pre-134
dissolved in 1.4 mL of ethanol and added to 8.6 mL of the PVP solution. A series of solutions135
with varied PCM/CAF contents was prepared as listed in Table 1. The ratio of PCM to CAF136
was selected to match that in commercial formulations (Laska et al., 1983). Mechanical137
stirring was applied for at least 20 min at room temperature to obtain homogeneous138
solutions. The conductivities of the spinning solutions were recorded using a PRIMO5139
conductivity meter (Hanna Instruments, Woonsocket, RI, USA).140
The spinning solutions were carefully placed into a plastic syringe (5 mL, BD, Sunderland,141
UK), with great care taken to avoid any air bubbles. A metal dispensing tip (spinneret; gauge142
20, 0.61 mm inner diameter, Nordson EFD, Dunstable, UK) was attached to the syringe. The143
positive electrode of a high voltage power DC supply (HCP35-35,000, FuG Elektronik,144
Rosenheim, Germany) was then connected to the spinneret. The grounded electrode was145
connected to a metal collector (17 x 17 cm2) wrapped with aluminum foil. Electrospinning146
was carried out under ambient conditions (22 ± 1°C and relative humidity 35 ± 3%). An147
electrical potential of 15 kV was applied across a fixed distance of 12 cm between the148
spinneret and the collector. The polymer solution was dispensed from the syringe at a feed149
rate of 1.2 mL/h using a syringe pump (78-9100C, Cole-Parmer, London, UK). Fibers were150
stored in a vacuum desiccator post-synthesis to facilitate the removal of residual organic151
solvents and moisture.152
153
154
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2.3 Characterization155
2.3.1 Thickness of the fiber mat156
2 mL of each spinning solution was spun onto Al foil, and three circular sections of 3 cm157
diameter cut out using a biopsy punch. The thickness of each section was measured by using158
a digital Vernier calliper. Results are reported as mean ± S.D.159
160
2.3.2 Folding endurance161
The folding endurance gives a measure of the brittleness of a film. 3 cm diameter circular162
sections of each mat (produced as detailed in 2.3.1) were repeatedly folded by hand at the163
same line until they broke or a visible crack was observed. The number of times a film can164
be folded without breaking or visibly cracking is defined as the folding endurance (Mundargi165
et al., 2007). Experiments were performed in triplicate, and data reported as mean ± S.D.166
167
2.3.3 pH of the fiber solution168
A 3 cm diameter section from each formulation was dissolved in 10 mL of distilled water and169
the pH was measured (pH 211 meter, Hanna Instruments, Woonsocket, RI, USA). Each170
experiment was carried out in triplicate and data are reported as mean ± S.D.171
172
2.3.4 Morphology173
The fiber morphologies were assessed using a scanning electron microscope (Quanta 200174
FEG ESEM, FEI, Hillsborough, OR, USA). Prior to examination, the samples were gold sputter-175
coated (20 nm) under argon to render them electrically conductive. Images were then176
recorded at an excitation voltage of 5 kV. The average fiber size was determined by177
measuring their diameters at over 50 points in SEM images, using the ImageJ software178
(National Institutes of Health, Bethesda, MD, USA). The porosities of the fiber mats were179
calculated using the method of Ghasemi-Mobarakeh et al. (Ghasemi-Mobarakeh et al.,180
2007).181
182
2.3.5 X-ray diffraction183
X-ray diffraction (XRD) patterns were obtained on a MiniFlex 600 diffractometer (RigaKu,184
Tokyo, Japan) with Cu Kα radiation (λ = 1.5148 Å). Data were recorded over the 2θ range 5 - 185
45° at 40 mV and 15 mA.186
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187
2.3.6 Differential scanning calorimetry188
Differential scanning calorimetry (DSC) analyses were carried out using a DSC Q2000189
calorimeter (TA Instruments, New Castle, DE, USA). Sealed samples were heated at 10 °C /190
min from 40 °C to 300 °C under a 50 mL / min flow of nitrogen. Recorded data were191
analysed using the TA Instruments Universal Analysis software.192
193
2.3.7 Fourier transform infrared spectroscopy194
Fourier transform infrared (FTIR) spectroscopy was conducted using a Spectrum 100 FTIR195
spectrometer (Perkin Elmer, Massachusetts, USA) fitted with an ATR attachment. The196
scanning range was 4000 – 600 cm−1, and the resolution set at 1 cm−1.197
198
2.4 HPLC analysis199
A high-performance liquid chromatography (HPLC) method was developed in order to200
detect PCM and CAF simultaneously. HPLC was performed using an Agilent 1260 Infinity201
instrument (Agilent Technologies, Santa Clara, CA, USA). The mobile phase consisted of 20 %202
v/v acetonitrile, 0.8 % v/v trifluoroacetic acid, and 79.2 % v/v distilled water. Analysis was203
carried out under isocratic conditions using a C18 column (00G-4326-60, Phenomenex,204
Macclesfield, UK). The column temperature was set to 40 °C, and the flow rate at 1 mL /205
min. 10 µL of each sample was injected, and chromatograms were recorded at 254 nm for 6206
min (to detect PCM) and at 276 nm for another 4 min (to detect CAF). The percentage drug207
loading was calculated using a pre-determined calibration curve prepared using a mixture of208
PCM and CAF.209
210
2.5 Wetting assays211
3 cm diameter circular sections were cut from the fiber mats using a biopsy cutter and212
placed in a Petri dish containing 15 mL of simulated saliva (NaCl 8.00g, KH2PO4 0.19g,213
Na2HPO4 2.38g, in 1L of distilled water: pH 6.8) at room temperature. The disintegration and214
dissolution of the fiber mats was recorded at 1000 frames per second using a high speed215
video camera (Fastcam SA3, Photron, Tokyo, Japan).216
217
218
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2.6 Dissolution studies219
The standard British Pharmacopoeia dissolution test is performed in 900 mL of a dissolution220
medium. However, this does not reflect the volume of the oral cavity (Hoffmann et al.,221
2011). Therefore a modified dissolution study was performed using a 1 cm long magnetic222
stirrer in a 7 cm diameter glass Petri dish. 15 mL of simulated saliva pre-warmed to 37 °C223
was placed in the Petri dish and stirred at 150 rpm on a multipoint stirrer (Cimarec™ iPoly224
15, ThermoScientific, Loughborough, UK). 200 µL of the supernatant was removed at pre-225
determined time points and replaced with 200 µL of pre-warmed simulated saliva to226
maintain a constant volume. Experiments were carried out in triplicate and results reported227
as mean ± S.D. The temperature remained at 37 ± 2 °C throughout the experiment.228
229
2.7 Molecular modelling230
Molecular mechanics in vacuo calculations were undertaken using HyperChem version231
8.0.10 (a molecular modelling software package). The structures of each of the compounds232
(Figure 1) were first generated with Accelrys Draw 4.1. A decameric PVP species was chosen233
to represent the polymer. Each structure was individually imported into HyperChem, and a234
3-D structure using preset bond angles and lengths produced (all hydrogen atoms were235
explicitly included). Initial geometric minimisation was next performed with the MM+ force236
field followed by a full energetic minimisation using the AMBER 3 (Assisted Model Building237
and Energy Refinement) force field. Nonbonded electrostatic interactions were calculated238
using bond dipole interactions in MM+ optimisation. For AMBER 3 minimisations, the239
distance-dependent dielectric constant was assigned a scale factor of 1, and the 1-4 scale240
factors (representing the nonbonded interactions between atoms separated by three241
atoms) were: electrostatic 0.5, and van der Waals 0.5. Both MM+ and AMBER 3 force fields242
were computed using a Polak-Ribiere conjugate gradient method finishing when the root243
mean square gradient reached 0.001 kcal / (Å mol). No cut-offs were applied. The energetic244
contributions to the total steric energy of the structures by bond stretching / compressing,245
bond angle deformations, torsional strain, van der Waals repulsions, hydrogen bonding and246
electrostatic repulsions were all considered. Combinations of the energetically minimised247
structures were then merged to create drug-polymer complexes. These complexes then248
underwent the same minimisation procedures.249
250
3. Results and discussion251
3.1 Electrospinning252
The polymer/active pharmaceutical ingredient (API) spinning solutions for used to make the253
fiber materials F0, F1, F2 and F3 were transparent and clear. For F4, concentrated raspberry254
flavor (2 µL / mL spinning solution) was also added to fabricate flavored nanofibers. The255
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raspberry flavor is expected to act as a taste masking agent, hiding the bitter taste of PCM,256
and also as a colouring agent: the spinning solution turned slightly pink upon addition of257
raspberry flavor. Details of the solutions and resultant fibers are presented in Table 1. The258
conductivities of the spinning solutions were measured, and found to be approximately the259
same regardless of the drug content and the presence or absence of the raspberry flavor260
(see Table 2).261
262
3.2 Thickness of the fiber mat263
The mean thicknesses of 3 cm diameter circular sections cut from electrospun mats of each264
formulation lie between ca. 121 µm and 131 µm (data are given in Table 2). This is entirely265
appropriate for an oral fast-dissolving film, and can be adjusted very easily by varying the266
collection time (i.e. the volume of solution processed). These values are comparable with267
those in the literature; for instance, Londhe has reported films of ca. 50 μm (Londhe and 268
Umalkar, 2012), while Cilurzo et al. have generated films of 120 – 131 μm thickness (Cilurzo 269
et al., 2011; Cilurzo et al., 2010) and systems of 88 – 420 μm were prepared by Ibrahim’s 270
team (Sayed et al., 2013).271
272
3.3 Folding endurance273
The folding endurance of 3 cm diameter circular sections of each fiber mat was assessed by274
hand-folding the sections along a fixed line, and the results are provided in Table 2. The275
folding endurance is seen to decease as the drug loading is increased, indicating that the276
fiber mat becomes more brittle with increasing drug loading. F3 has a folding endurance of277
only 6.67 times, and hence is very likely to be too brittle for use as an oral film. However,278
the other fibres have high folding endurance of > 20 times, thus indicating their high279
potential in this area.280
281
3.4 pH of the fiber solution282
Solutions prepared by dissolving a 3 cm diameter circular section of the fiber mats in 10 mL283
deionised water were found to have pH values lying in the range 6.7 – 7.2 (see Table 2).284
Acidic or alkaline pHs may cause damage to the oral mucosa, and so the pH of the dissolved285
oral fast dissolving film should be close to the neutral pH of the mucosa (El-Mahrouk et al.,286
2014). Mucosal pH values have been found to vary between 6.28 (buccal mucosa) and 7.34287
(palate) (Aframian et al., 2006). The materials fabricated here hence give solutions with pHs288
close to those observed for the oral mucosa, and can be expected not to cause mucosal289
damage upon administration.290
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291
3.5 Fiber morphology292
Scanning electron microscopy (SEM) images of the electrospun products are given in Figure293
2. The SEM data show that the composite fibers were cylindrical in shape, with smooth294
surfaces and no secondary particles visible. No bead-on-string morphology can be observed.295
This indicates that both PCM and CAF are encapsulated homogeneously in the PVP fiber296
matrices. The fabricated fibers are oriented in a random manner. The mean fiber diameters297
(Table 3) are F1: 443 ± 93 nm; F2: 750 ± 222 nm; F3: 1553 ± 435 nm and F4: 518 ± 175 nm298
respectively. The fiber diameter thus appears to increase with the drug loading [F1 contains299
PCM 10.27 % / CAF 1.37 % (w/w), while F3 is PCM 35.10% / CAF 4.56% (w/w)]. Both F2 and300
F4 comprise 21.87 % PCM and 2.89 % CAF (w/w), but the latter also incorporates a301
raspberry flavoring. Since the F4 fibers are somewhat narrower than the F2 material, it302
seems that the incorporation of even a small amount of flavoring causes a decrease in fiber303
diameter. The complex nature of the raspberry flavour, which is not a single chemical entity304
but rather a mixture of compounds, makes it difficult to ascertain the precise cause of this305
size variation. The porosities of the fiber mats were calculated to lie in the range of 81.8 –306
83.6 %, being largely invariant with API loading and the presence or absence of flavor.307
The fiber mats were found to be very resilient to cutting, and could be formed into a range308
of different shapes appropriate for use as oral films. Photographs of the F4 fiber mat cut309
into different shapes are shown in Figure 3.310
311
3.6 X-ray diffraction312
X-ray diffraction was undertaken to examine the physical state of the components of the313
composite nanofibers. Characteristic reflections [see Figure 4 (a)] of CAF appear at314
diffraction angles 2θ of 11.24°, 25.64° and 26.24°, and for PCM distinct reflections can be 315
observed at 17.18°, 22.66°, and 25.58°. A physical mixture of PVP, PCM and CAF in the same316
ratios as F2 (F5) shows the diffraction features of both PCM and CAF superimposed on a317
broad background from the amorphous PVP polymer. The pattern of fibers containing only318
PVP [F0; Figure 4 (b)] was characterized by the absence of any diffraction peaks, with only a319
broad halo observed: this confirms the PVP to be amorphous after electrospinning. In the320
patterns of the drug-loaded nanofibers, the characteristic reflections of PCM or CAF cannot321
be seen, while the characteristic humps of amorphous materials are observed. This suggests322
that both active ingredients were present in amorphous form in the fibers.323
324
325
3.7 Differential scanning calorimetry326
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The differential scanning calorimetry (DSC) curves of pure PCM and CAF [see Figure 5(a)]327
each show a clear melting endothermic peak. The PCM form I melt can be seen at 169.4 °C.328
For CAF, the principal feature in the thermogram is the melting of form I of the API at 238.4329
°C. There is however a small additional endothermic peak at around 160 °C, attributed to330
the presence of a small amount of caffeine form II in the material provided (Hubert et al.,331
2011). The physical mixture (F5) shows a broad shallow endothermic peak below 100 °C due332
to the dehydration of PVP, followed by a broad peak believed to correspond to melting of333
PCM centred at around 150 °C. The CAF melting point cannot be observed, probably334
because of its low loading in the physical mixture.335
The DSC thermograms of the composite nanofibers do not show any melting peaks, only a336
broad dehydration endothermic peak ranging from 40 to 110 °C, with a peak at 80 - 83 °C.337
This suggested that PCM and CAF were not present as crystalline materials, but had been338
converted into an amorphous state in the fibers.339
340
3.8 FTIR spectroscopy341
Compatibility between the drug and polymer is important for the formation of nanofibers342
during electrospinning and for the stability of the resultant materials. If the drug is not343
compatible with the polymer, then solid phase separation will be observed. The interactions344
between the drug and the polymer can be probed using IR spectroscopy.345
The FTIR spectrum of pure PCM is shown in Figure 6(a). The broad peak between around346
3000 and 3700 cm−1 is assigned as H-bonded O-H and N–H stretching vibrations.347
Absorptions at ca. 2880 and 2950 cm-1 denote C-H stretches. The peaks at 1644, 1560 and348
1511 are assigned to the C=O stretching and N-H bending vibrations of the amide group. A349
very sharp peak at 835 cm-1 is also visible. The infrared spectra of CAF [see Figure 6(a)]350
shows an absorbance at 1650 cm-1 corresponding to the C=O stretch of the amide group.351
There are also peaks at around 1435 and 1504 cm-1 (C=C stretching), and between 1330 and352
1105 cm-1 which may be ascribed to the C-N amide stretches. Sharp bands at 835, 807, and353
796 cm-1 are present in the fingerprint region. The spectrum of the pure PVP fibers F0354
[Figure 6 (b)] shows broad bands at 3650 – 3050 cm-1 (H-bonded O-H stretches from residual355
water) and 2840 – 3010 cm−1 (C–H stretching), as well as peaks at 1643 cm−1 (C=O) and at356
1290 cm−1 (C–N stretch) (Borodko et al., 2006).357
The FTIR spectra of the medicated fibers comprise a composite of those from PVP and the358
drugs. They show two main peaks at around 1645 – 1650 cm−1 and 1290 cm−1 due to the359
C=O and C-N stretch from PVP. Peaks can also be seen corresponding to the PCM and CAF,360
for instance at 1550 cm-1 (PCM N-H bend), 833 cm-1 (PCM/CAF fingerprint), and 793 cm-1361
(CAF fingerprint). It is hard to unambiguously assign peaks because of the complexity of the362
spectra, but small shifts in peak positions (e.g. from 1643 in pure PVP to 1650 cm-1 in the363
fibers) indicate that there may be intermolecular interactions between the drugs and PVP.364
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365
3.9 Molecular modelling366
Although interactions between the APIs and polymer are suggested by the IR spectra, the367
complexity of the spectra mean that it is impossible to characterise these in detail.368
Molecular models of PCM, CAF, PVP, and the API-polymer complexes were constructed369
using the Hyperchem software. The geometric preferences for the energetically minimised370
API-polymer systems are depicted in Figure 7. The energetic contributions to the overall371
steric energy for the drug-polymer complexes and the individual API molecules and PVP372
decamer are given in Table 4. Stabilisation of the complexes is indicated by a negative373
difference (∆E) between the total steric energy of the complex and the sum of the total 374
steric energies of the individual molecules. The ∆E values for PVP-PCM, and PVP-CAF, and 375
PVP-PCM-CAF are -19.126, -13.105, and -30.451 kcal mol-1 respectively. These negative376
values clearly confirm that there are interactions between the PVP polymer and the APIs.377
The ∆E value is more negative for PCM than CAF, indicating stronger interactions with the 378
former.379
380
3.10 Drug loading381
The percentage drug loadings in the fibers were determined by HPLC. A bespoke method382
was devised to permit the observation of both APIs in the same experiment (see Section383
2.4). The resultant data are given in Figure 8. Solutions of PCM and CAF were first run384
separately and PCM observed at an elution time of 4.87 min, and CAF at 7.92 min. Similar385
results were observed for the mixture of PCM and CAF, where elution was noted at 4.78 min386
for PCM and at 7.62 min for CAF. The dissolved fiber formulations show peaks at the same387
retention times as the pure drug materials (see Figure 8), confirming that neither API was388
degraded during the electrospinning process. Following construction of a calibration curve,389
the drug loading was determined for the fibers: the results are presented in Table 5. It can390
be seen that the formulations generally show very high (> 90 %) loading of both drugs, with391
the exception of F3 where the PCM loading is slightly below 90 %.392
393
394
3.11 Wetting assays and dissolution studies395
The PCM/CAF-loaded fiber mats were found to be wetted and to disintegrate very rapidly in396
simulated saliva. The process was recorded using a standard video camera for all397
formulations, and using high-speed camera for F2 and F4. All the formulations appeared to398
disintegrate within < 3 s when recorded using the standard camera, but it proved impossible399
to discern the disintegration time more precisely. Further observations were thus carried400
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out using a high-speed camera for the F2 and F4 fiber mats. Both were seen to disintegrate401
within around 320 ms. This is clearly visible from the photographs given in Figure 9402
(depicting F4). These disintegration times are exceptionally rapid, and eminently suitable for403
the preparation of oral fast-dissolving films: other researchers preparing such systems404
report disintegration times of 10 – 20 s (Cilurzo et al., 2011; Cilurzo et al., 2010; Londhe and405
Umalkar, 2012).406
Dissolution studies (see Figure 10) demonstrated that with the physical mixture (F5), 48 ±407
5.6 % of the incorporated PCM and 87 ± 2.5 % of the CAF were released within 6 minutes.408
Within 30 s, fibers F1, F4 and F5 respectively released 38 ± 12 %, 66 ± 7.0 % and 4.5 ± 1.8 %409
of their PCM loading, and 52 ± 12 %, 72 ± 11 % and 37 ± 5.7 % of the incorporated CAF. The410
poor folding endurance of the F3 fibers indicated that they were not suitable for oral films,411
and thus dissolution studies were not performed.412
The rapid dissolution observed with the PCM/CAF loaded fiber mats can be attributed to the413
amorphous physical state of the APIs in the formulations, the high surface area and high414
porosity of the of the drug loaded fibers, and the exceptional hydrophilicity of PVP. API415
release from a formulation occurs at its interface with the buffer solution; the high surface416
area to volume ratio of the fiber mats ensures that this contact area is very high, thus417
accelerating release. The amorphous nature of the API removes the need to overcome any418
crystalline lattice enthalpy, again facilitating dissolution. Finally, the hygroscopicity of PVP419
also encourages the mat to disintegrate, dissolve, and free its drug loading into solution.420
Attempts were made to fit various kinetic models to the experimental data, but these were421
unsuccessful owing to the very rapid nature of the release processes.422
For all the formulation studied, the CAF release is seen to be more rapid. This is consistent423
with its higher solubility under the dissolution conditions [the respective solubilities for CAF424
and PCM are ca. 21.6 mg ml-1 vs. 14.0 mg ml-1 in water at 25 °C (http://www.drugbank.ca/)].425
It is also consistent with the molecular modelling results (Section 3.9) which show stronger426
interactions between PCM and PVP than between the polymer and CAF. The difference in427
release rate between PCM and CAF is very much less for the fiber formulations than for the428
physical mixture, presumably a result of the amorphous nature of the APIs in the former429
ameliorating any differences in lattice enthalpy. Similar results were recorded by Khan and430
Craig when they performed dissolution studies on solid dispersions of PCM and CAF (Khan431
and Craig, 2003).432
Overall, the systems prepared in this work have great potential as oral fast dissolving films.433
Both drugs can be successfully loaded into the fibers in amorphous physical form, and very434
rapid disintegration (< 0.5 s) and release of drug (< 150 s) are observed. The pH of the fiber435
solution is close to neutral, and hence no mucosal irritation is to be expected. A flavoring436
can be incorporated into the fibers to ameliorate issues of bitterness. Such formulations437
could thus have great utility as paediatric medicines. The British National Formulary for438
Children (BNF-C) suggests that an appropriate dose of paracetamol for the treatment of pain439
a child of 8 years old is between 240 and 375 mg four times a day (BNF-C, 2014). The loading440
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in F4 is 21.87 % w/w; thus a mass of formulation of between 1100 and 1715 mg would be441
needed for each dose. For a child of six months to two years in age, the required dose is 120442
mg, demanding a fiber mass of ca. 550 mg. This mass of formulation could easily be443
prepared and applied by mouth, particularly at the lower end of the dosage regimen. In444
addition, further optimisation could increase the drug loading to reduce the formulation445
mass required.446
447
4. Conclusions448
In this study we successfully produced fast-dissolving drug delivery systems for the449
simultaneous release of paracetamol (PCM) and caffeine (CAF). This was achieved by450
processing them into electrospun fibers using polyvinylpyrrolidone (PVP) as the filament451
forming agent. Scanning electron microscopy showed that the composite nanofibers had452
smooth surfaces and average fiber diameters between 400 – 1600 nm. IR spectroscopy453
results combined with molecular modelling demonstrated that there were clear454
intermolecular interactions between paracetamol, caffeine, and PVP. X-ray diffraction and455
differential scanning calorimetry studies indicated that both drugs were fully converted into456
the amorphous form in the fibers. Both APIs were observed to remain intact after spinning,457
with drug loadings close to 100 % of the theoretical value. In wetting tests, the drug loaded458
fiber mats disintegrated within 0.5 s, and dissolution studies revealed that all the embedded459
drug was freed into solution in less than 150 s: a significant improvement over the pure APIs460
and the physical mixture. A flavoring agent can easily be incorporated into the fibers to461
overcome problems with bitterness. These flavored fibers can be used as potential drug462
delivery systems, especially for the paediatric population.463
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